Lupin Launches Rocuronium Bromide Injection in US, Expanding Anesthesia Portfolio
November 17, 2023: Global pharmaceutical company Lupin Limited (Lupin) announced the launch of Rocuronium Bromide Injection, 50 mg/5 mL (10 mg/mL) and 100 mg/10 mL (10 mg/mL) Multiple-Dose Vials, in the United States. This launch marks a significant expansion of Lupin’s anesthesia portfolio and strengthens its presence in the US market.
Rocuronium Bromide Injection is a generic version of Zemuron® Injection, a neuromuscular blocker used to facilitate rapid sequence and routine tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. It is indicated for both inpatients and outpatients.
The launch of Rocuronium Bromide Injection results from an Abbreviated New Drug Application (ANDA) approval from the United States Food and Drug Administration (US FDA). Lupin’s alliance partner, Caplin Steriles Limited (Caplin), received the ANDA approval for the product.
Rocuronium Bromide Injection is expected to generate significant revenue for Lupin, as the branded product, Zemuron®, had estimated annual sales of USD 54 million in the US, according to IQVIA MAT August 2023.
“The launch of Rocuronium Bromide Injection is a major milestone for Lupin and demonstrates our commitment to providing high-quality, affordable generic medications to patients in the US,” said Lupin’s CEO. “We are confident that this product will be well-received by healthcare professionals and patients alike.”
The launch of Rocuronium Bromide Injection is part of Lupin’s ongoing strategy to expand its presence in the US market. The company has a strong pipeline of products in development, including several other generic injectables.
Lupin is a leading global pharmaceutical company committed to providing high-quality, affordable medications to patients worldwide. The company has a strong presence in the US, India, and other emerging markets. Lupin is committed to innovation, research, and development and has a strong pipeline of products in development.